15:53 , Mar 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest promoting LPPR1 expression or inhibiting LPAR1 could help treat SCI. In primary mouse cortical neurons subjected to scrape injury, overexpression of LPPR1 increased regeneration of...
12:56 , Mar 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting LPAR1-ENPP2 signaling could help treat bronchiolitis obliterans syndrome following lung transplantation. In lung mesenchymal cells from lung transplant patients, ENPP2 levels were higher in patients with bronchiolitis...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co.’s deal to license worldwide rights to Nitto Denko Corp.’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS now owns...
07:00 , Oct 15, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity was down slightly in 3Q15 compared with the previous quarter, with 61 partnerships announced during that span. Big pharmas and biotechs continue to pair up with public and academic institutions at a high...
08:00 , Feb 5, 2015 |  BC Innovations  |  Translation in Brief

Proteome atlas

It's taken over a decade to collect the data, but a group of Swedish researchers has developed the Human Protein Atlas, a tissue-based map of the human proteome that describes where every protein is expressed...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Lysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1) In vitro and...
08:00 , Nov 14, 2013 |  BC Innovations  |  Tools & Techniques

Scleroderma models: skin in the game

Systemic scleroderma involves fibrosis of the skin and internal organs, but its etiology is poorly understood and it has no known genetic causes-factors that have hampered the development of models and, in turn, therapies. Now, a...
07:00 , Mar 12, 2012 |  BioCentury  |  Strategy

Greasing the public-private interface

Bristol-Myers Squibb Co. and Duke University think their new partnership could be a model for other pharmas and universities to help speed all stages of drug development from preclinical research to post-marketing community outreach. BMS and...
02:07 , Feb 29, 2012 |  BC Extra  |  Company News

Bristol-Myers, Duke institute in research partnership

Bristol-Myers Squibb Co. (NYSE:BMY) and the Duke Translational Medicine Institute will co-develop and co-implement the protocol for a Phase II trial of the pharma's BMS-986202 (formerly AM152) for idiopathic pulmonary fibrosis (IPF). The trial is...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Potent play

Potent play Strategic investors Merck Serono Ventures and Novo A/S launched Galecto Biotech AB last week with a seed round of more than €5 million ($6.5 million) that is expected to get the biotech into the...